IRVINE, Calif.–(BUSINESS WIRE)–Endologix, Inc. (Nasdaq:ELGX), a developer and marketer of innovative treatments for aortic disorders, announced today that it has received Investigational Device Exemption (“IDE”) approval from the United States Food and Drug Administration (“FDA”) to commence a new pivotal study to evaluate the safety and effectiveness of the Nellix […]
Other News
Endologix Announces Exclusive Distributor Agreement with Boston Scientific for the Chinese Market
IRVINE, Calif.–(BUSINESS WIRE)–Endologix, Inc. (Nasdaq: ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced an agreement naming Boston Scientific Corporation (NYSE: BSX) the exclusive distributor for Endologix products in China. The long-term agreement includes distribution rights to Endologix’s current EndoVascular Aneurysm Repair (EVAR) and Endovascular Aneurysm […]
Caladrius Biosciences Reports 2019 Second Quarter and First Six Months Financial Results and Provides Corporate Update
Confirmatory Phase 3 Study Protocol Finalized for CLBS14 in No-Option Refractory Disabling Angina Conference call begins today at 4:30 p.m. Eastern time BASKING RIDGE, N.J., Aug. 08, 2019 (GLOBE NEWSWIRE) — Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a late-stage therapeutics development biopharmaceutical company pioneering advancements of cell […]
Endologix Reports Second Quarter 2019 Financial Results
IRVINE, Calif.–(BUSINESS WIRE)–Endologix, Inc. (the “Company”) (NASDAQ:ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced financial results for the second quarter ended June 30, 2019. “We are pleased with our second quarter results, as stronger execution led to a sequential improvement in revenue,” commented John Onopchenko, […]
Corindus Vascular Robotics Announces Definitive Agreement to Be Acquired by Siemens Healthineers
— Corindus Stockholders to Receive $4.28 Per Share — — All-Cash Transaction Valued at Approximately $1.1 Billion — WALTHAM, Mass.–(BUSINESS WIRE)–Corindus Vascular Robotics (NYSE American: CVRS), a leading developer of precision vascular robotics, today announced that it has entered into a definitive merger agreement to be acquired by Siemens Healthineers AG. […]
Neovasc Announces Second Quarter 2019 Financial Results
NASDAQ, TSX: NVCN Recent Highlights Received Guidance from FDA to explore a potential Humanitarian Device Exemption Pathway for Neovasc Reducer™ (the “Reducer”) for CCS class IV patients and to meet for another Sprint discussion Closed Private Placement of Convertible Debt and Common Shares for Gross Proceeds of US$11.5 Million Regained Compliance […]
BioCardia Announces Issuance of European Patent for Breakthrough Diagnostic Assay for Patient Selection Prior to Cardiac Cell Therapy Delivery
SAN CARLOS, Calif., Aug. 08, 2019 (GLOBE NEWSWIRE) — BioCardia®, Inc. [OTC: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced that the European Patent Office has issued the Company Patent No: 3063172 for “Methods of Measuring Potential for Therapeutic Potency and Defining Dosages for Autologous […]
MyoKardia Reports Second Quarter 2019 Financial Results
Announces Last Patient to be Enrolled in EXPLORER-HCM Phase 3 during the Week of August 12th; Topline Data Accelerated to 2nd Quarter 2020 Topline Phase 2 Clinical Data from MAVERICK-HCM and MYK-491 on Track for Fourth Quarter 2019 Company to Host Conference Call and Webcast Today at 4:30 p.m. ET (1:30 p.m. […]
Stereotaxis Announces $25 Million Private Placement
ST. LOUIS, Aug. 08, 2019 (GLOBE NEWSWIRE) — Stereotaxis (OTCQX: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that it has entered into a securities purchase agreement with select institutional investors for a $25 million private placement. In this private placement, Stereotaxis is selling […]
Stereotaxis Reports 2019 Second Quarter Financial Results
ST. LOUIS, Aug. 08, 2019 (GLOBE NEWSWIRE) — Stereotaxis (OTCQX: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today reported financial results for the second quarter ended June 30, 2019. In a separate press release issued concurrently with this release, Stereotaxis announced a $25 million private […]
Recent
Popular
- No commented posts yet